<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidermal growth factor receptor inhibitors (EGFRIs) have become an integral part of therapy for many types of solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The drug class has proven to be effective without causing many of the side-effects associated with chemotherapy or other growth factor receptor inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000421'>Epistaxis</z:hpo>, a common side-effect of Vascular Endothelial Growth Factor inhibitors, is rarely noted with EGFRIs </plain></SENT>
<SENT sid="3" pm="."><plain>We report on one patient, a 51-year-old man with metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, who developed severe <z:hpo ids='HP_0000421'>epistaxis</z:hpo> with the use of panitumumab </plain></SENT>
<SENT sid="4" pm="."><plain>We discuss the other reported cases of EGFRIs causing <z:hpo ids='HP_0000421'>epistaxis</z:hpo> and hypothesize on possible mechanisms by which this drug class might cause mucosal <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
</text></document>